Watch for the Phase 3 CLBP 12-month pain reduction readout next year and the formal FDA meeting minutes for the rexlemestrocel-L BLA filing. Adult SR-aGvHD trial enrollment progress and Ryoncil revenue trajectory in subsequent quarters will be key catalysts.
Price Chart
Executive Summary
Mesoblast reported Q1 FY2027 Ryoncil net revenue of $28M, up 44% YoY, and reduced net operating cash spend to $2.1M, an 86% improvement from $14.9M a year ago. The company completed enrollment in the Phase 3 CLBP trial and received FDA confirmation that the BLA for rexlemestrocel-L in LVAD patients may proceed. Cash at quarter end was $98.5M with 46.3 quarters of funding available.
Key Financial Metrics
Key Facts
- Ryoncil net revenue of $28M for Q1 FY2027, a 44% increase YoY
- Net operating cash spend of $2.1M, an 86% improvement from $14.9M in the prior year period
- Cash and cash equivalents of $98.5M at September 30, 2026
- Completed treatment of all patients in the 350-patient Phase 3 pivotal trial of rexlemestrocel-L for chronic low back pain
- FDA confirmed BLA filing may proceed for rexlemestrocel-L in prevention of life-threatening GI bleeding in end-stage heart failure patients with LVAD
- Registration trial for Ryoncil expansion into adults with SR-aGvHD has commenced and is enrolling patients
- FDA approved an additional potency assay (TIBA) for Ryoncil manufacturing scale-up
- September had the highest number of new patient starts per month for Ryoncil
- Company has $125M credit facility fully drawn at 8% interest, secured solely by Temcell royalty
Financial Impact
Ryoncil revenue of $28M (44% YoY growth); operating cash burn reduced 86% to $2.1M; cash position $98.5M
Risk Factors
- Company remains unprofitable with accumulated losses of $1.07B per the prior annual report
- Ryoncil revenue subject to seasonality and depends on commercial execution
- Pipeline candidates (rexlemestrocel-L) are still in clinical development with regulatory and clinical risk
- Full $125M credit facility is drawn, limiting additional debt capacity
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001345099-26-000093 |
| Document: form6-kxpressreleasecoverf.htm | 0001345099-26-000093 |
| Document: 0001345099-26-000093-index-headers.html | 0001345099-26-000093 |
| Document: 0001345099-26-000093-index.html | 0001345099-26-000093 |
| Document: 0001345099-26-000093.txt | 0001345099-26-000093 |
| 6-K Earnings Context (Synthetic) | 0001345099-26-000093 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 29, 2026 3d ago | 6-K | No price | awaiting T+1 | awaiting T+1 | No price |
Oct 28, 2026 4d ago | Press Release | $15.67 $15.16 | ▼ −3.25% | ▼ −1.48% | $15.16 (−3.25%) |
Oct 15, 2026 17d ago | 6-K | $13.28 $11.95 | ▼ −10.02% | ▼ −10.44% | $15.16 (+14.16%) |
Oct 15, 2026 17d ago | 6-K | $13.95 $13.28 | ▼ −4.80% | ▼ −3.70% | $15.16 (+8.67%) |
Oct 13, 2026 19d ago | 6-K | $13.90 $13.79 | ▼ −0.76% | ▲ +0.33% | $15.16 (+9.10%) |
Sep 23, 2026 5w ago | 6-K | $15.48 $15.12 | ▼ −2.33% | ▼ −2.87% | $15.16 (−2.07%) |
Aug 27, 2026 9w ago | 20-F | $18.18 $17.44 | ▼ −4.07% | ▼ −3.84% | $15.16 (−16.61%) |
Aug 26, 2026 9w ago | Press Release | $18.18 $17.44 | ▼ −4.07% | ▼ −3.84% | $15.16 (−16.61%) |
Aug 24, 2026 9w ago | 6-K | $16.64 $17.19 | ▲ +3.31% | ▲ +2.99% | $15.16 (−8.89%) |
Aug 16, 2026 11w ago | Press Release | $17.02 $16.67 | ▼ −2.06% | ▼ −1.38% | $15.16 (−10.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers